179 related articles for article (PubMed ID: 33602035)
1. The rationale for use of clinically defined outcomes in assessing the impact of pneumococcal conjugate vaccines against pneumonia.
Gessner BD; Isturiz R; Snow V; Grant LR; Theilacker C; Jodar L
Expert Rev Vaccines; 2021 Mar; 20(3):269-280. PubMed ID: 33602035
[No Abstract] [Full Text] [Related]
2. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
Gessner BD; Jiang Q; Van Werkhoven CH; Sings HL; Webber C; Scott D; Gruber WC; Grobbee DE; Bonten MJM; Jodar L
Vaccine; 2019 Jul; 37(30):4147-4154. PubMed ID: 31155413
[TBL] [Abstract][Full Text] [Related]
3. Pneumococcal serotypes in adults hospitalized with community-acquired pneumonia in Greece using urinary antigen detection tests: the EGNATIA study, November 2017 - April 2019.
Liapikou A; Konstantinidis A; Kossyvaki V; Skiadas J; Menegas D; Méndez C; Beavon R; Begier E; Gessner BD; Milionis H; Tsimihodimos V; Baxevanos G; Argiriadou T; Terrovitou C; Toumbis M;
Hum Vaccin Immunother; 2022 Nov; 18(5):2079923. PubMed ID: 35703733
[TBL] [Abstract][Full Text] [Related]
4. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
Webber C; Patton M; Patterson S; Schmoele-Thoma B; Huijts SM; Bonten MJ;
Vaccine; 2017 Mar; 35(9):1266-1272. PubMed ID: 28173960
[TBL] [Abstract][Full Text] [Related]
5. 13-Valent vaccine serotype pneumococcal community acquired pneumonia in adults in high clinical risk groups.
Daniel P; Rodrigo C; Bewick T; Sheppard C; Greenwood S; McKeever TM; Trotter C; Lim WS
Vaccine; 2018 Mar; 36(12):1614-1620. PubMed ID: 29439865
[TBL] [Abstract][Full Text] [Related]
6. Impact of the pediatric 13-valent pneumococcal conjugate vaccine on serotype distribution and clinical characteristics of pneumococcal pneumonia in adults: The Japan Pneumococcal Vaccine Effectiveness Study (J-PAVE).
Sando E; Suzuki M; Furumoto A; Asoh N; Yaegashi M; Aoshima M; Ishida M; Hamaguchi S; Otsuka Y; Morimoto K
Vaccine; 2019 May; 37(20):2687-2693. PubMed ID: 30975569
[TBL] [Abstract][Full Text] [Related]
7. Pneumococcal conjugate vaccine against serotype 3 pneumococcal pneumonia in adults: A systematic review and pooled analysis.
McLaughlin JM; Jiang Q; Gessner BD; Swerdlow DL; Sings HL; Isturiz RE; Jodar L
Vaccine; 2019 Oct; 37(43):6310-6316. PubMed ID: 31522807
[TBL] [Abstract][Full Text] [Related]
8. The Evolution and Distribution of Pneumococcal Serotypes in Adults Hospitalized With Community-Acquired Pneumonia in Spain Using a Serotype-Specific Urinary Antigen Detection Test: The CAPA Study, 2011-2018.
Torres A; Menéndez R; España PP; Fernández-Villar JA; Marimón JM; Cilloniz C; Méndez R; Egurrola M; Botana-Rial M; Ercibengoa M; Méndez C; Cifuentes I; Gessner BD;
Clin Infect Dis; 2021 Sep; 73(6):1075-1085. PubMed ID: 33851220
[TBL] [Abstract][Full Text] [Related]
9. Recalibrated estimates of non-bacteremic and bacteremic pneumococcal community acquired pneumonia in hospitalized Canadian adults from 2010 to 2017 with addition of an extended spectrum serotype-specific urine antigen detection assay.
LeBlanc JJ; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang ALS; Gillis HD; Martin I; Demczuk WHB; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy AE; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
Vaccine; 2022 Apr; 40(18):2635-2646. PubMed ID: 35315326
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.
Prato R; Fortunato F; Cappelli MG; Chironna M; Martinelli D
BMJ Open; 2018 Mar; 8(3):e019034. PubMed ID: 29581200
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
Lawrence H; Pick H; Baskaran V; Daniel P; Rodrigo C; Ashton D; Edwards-Pritchard RC; Sheppard C; Eletu SD; Litt D; Fry NK; Rose S; Trotter C; McKeever TM; Lim WS
PLoS Med; 2020 Oct; 17(10):e1003326. PubMed ID: 33095759
[TBL] [Abstract][Full Text] [Related]
12. Epidemiology of hospitalised paediatric community-acquired pneumonia and bacterial pneumonia following the introduction of 13-valent pneumococcal conjugate vaccine in the national immunisation programme in Japan.
Takeuchi N; Naito S; Ohkusu M; Abe K; Shizuno K; Takahashi Y; Omata Y; Nakazawa T; Takeshita K; Hishiki H; Hoshino T; Sato Y; Ishiwada N
Epidemiol Infect; 2020 Apr; 148():e91. PubMed ID: 32299523
[TBL] [Abstract][Full Text] [Related]
13. Multicountry Review of Streptococcus pneumoniae Serotype Distribution Among Adults With Community-Acquired Pneumonia.
Grant LR; Begier E; Theilacker C; Barry R; Hall-Murray C; Yan Q; Pope V; Pride MW; Jodar L; Gessner BD
J Infect Dis; 2024 Jan; 229(1):282-293. PubMed ID: 37665210
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of 13-valent pneumococcal conjugate vaccine against community acquired pneumonia among children in China, an observational cohort study.
Zhang T; Zhang J; Shao X; Feng S; Xu X; Zheng B; Liu C; Dai Z; Jiang Q; Gessner BD; Chen Q; Zhu J; Luan L; Tian J; Zhao G
Vaccine; 2021 Jul; 39(33):4620-4627. PubMed ID: 34253417
[TBL] [Abstract][Full Text] [Related]
15. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
Suaya JA; Jiang Q; Scott DA; Gruber WC; Webber C; Schmoele-Thoma B; Hall-Murray CK; Jodar L; Isturiz RE
Vaccine; 2018 Mar; 36(11):1477-1483. PubMed ID: 29429807
[TBL] [Abstract][Full Text] [Related]
16. Herd effects of child vaccination with pneumococcal conjugate vaccine against pneumococcal non-invasive community-acquired pneumonia: What is the evidence?
van Werkhoven CH
Hum Vaccin Immunother; 2017 May; 13(5):1177-1181. PubMed ID: 27937061
[TBL] [Abstract][Full Text] [Related]
17. Pneumococcal conjugate vaccine use in adults.
Isturiz RE; Schmoele-Thoma B; Scott DA; Jodar L; Webber C; Sings HL; Paradiso P
Expert Rev Vaccines; 2016; 15(3):279-93. PubMed ID: 26651847
[TBL] [Abstract][Full Text] [Related]
18. Pneumococcal conjugate serotype distribution and predominating role of serotype 3 in German adults with community-acquired pneumonia.
Forstner C; Kolditz M; Kesselmeier M; Ewig S; Rohde G; Barten-Neiner G; Rupp J; Witzenrath M; Welte T; Pletz MW;
Vaccine; 2020 Jan; 38(5):1129-1136. PubMed ID: 31761500
[TBL] [Abstract][Full Text] [Related]
19. Pneumococcal conjugate vaccination response in patients after community-acquired pneumonia, differences in patients with S. pneumoniae versus other pathogens.
Wagenvoort GHJ; Vlaminckx BJM; van Kessel DA; Geever RCL; de Jong BAW; Grutters JC; Bos WJW; Meek B; Rijkers GT
Vaccine; 2017 Sep; 35(37):4886-4895. PubMed ID: 28802755
[TBL] [Abstract][Full Text] [Related]
20. Age-stratified burden of pneumococcal community acquired pneumonia in hospitalised Canadian adults from 2010 to 2015.
LeBlanc J; ElSherif M; Ye L; MacKinnon-Cameron D; Ambrose A; Hatchette TF; Lang AL; Gillis HD; Martin I; Demczuk WH; LaFerriere C; Andrew MK; Boivin G; Bowie W; Green K; Johnstone J; Loeb M; McCarthy A; McGeer A; Semret M; Trottier S; Valiquette L; Webster D; McNeil SA
BMJ Open Respir Res; 2020 Mar; 7(1):. PubMed ID: 32188585
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]